Guy Young/LinkedIn
Jan 2, 2026, 03:50
Emicizumab in Infants: Not Just Cost-effective but Mandatory
Flora Peyvandi, Professor of Internal Medicine at the University of Milan and former President of ISTH, shared a post on X:
“Emicizumab in infants: not just cost-effective but mandatory.”
Author: Guy Young
Read the full article.
More posts by Flora Peyvandi on Hemostasis Today.
-
Apr 3, 2026, 05:59Nathan Connell: How the 2021 VWD Guidelines Are Actually Changing Real – World Practice
-
Apr 3, 2026, 05:28Tareq Abadl: How Iron Profile Reveals Hidden Insights about Blood Health and Iron Balance
-
Apr 3, 2026, 04:49Niraj Sharma: Breaking News Special Edition, CHAMPION-AF, CLOSURE-AF, PRAGUE-17, and Why LAAC Still Does Not Dethrone Contemporary Anticoagulation
-
Apr 2, 2026, 18:32Niyas Khalid: A Rare Case of Venous Ischemic Pancreatitis Redefining Diagnosis
-
Apr 2, 2026, 18:16Saravanan Subramaniam: How Extracellular Histones Act as Key Drivers of Thromboinflammation
-
Apr 2, 2026, 18:06Rob Molhoek Brings Invaluable Insights on Stroke Awareness and Care Improvements – Stroke Foundation
-
Apr 2, 2026, 17:21Paul Bolaji: Phase 2 of the Nigeria National Stroke Registry Is Now Live
-
Apr 2, 2026, 17:13Catherine Jennings: Marking Today as an Important Step Forward for Patients With PE
-
Apr 2, 2026, 17:11Arun V. J: Our Clinical Audit on Transfusion Safety Selected for Presentation at CAHOCON 2026